Publications of Wendy Kimryn Rathmell - ReachNC

60 Publications

This is a list of publications by this researcher, listed chronologically starting with the most recent first. New publications appear in this list weekly. The source of publications and 'cited by' data for this application is Scopus.

sort by year | cited by

Select All | Save icon

Export

1.
2013

Paulo A. Gameiro; Juanjuan Yang; Ana M. Metelo; Rocio Pérez-Carro; Rania Baker; Zongwei Wang; Alexandra Arreola; W. Kimryn Rathmell; Aria Olumi; Pilar López-Larrubia; et al.

In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation
Cell Metabolism. 2013;17(3):372-385.

0
2.
2013

Payal Kapur; Samuel Peña-Llopis; Alana Christie; Leah Zhrebker; Andrea Pavía-Jiménez; W Kimryn Rathmell; Xian-Jin Xie; James Brugarolas

Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: A retrospective analysis with independent validation
The Lancet Oncology. 2013;14(2):159-167.

0
3.
2013

Sarah A. Gallagher; Angela B. Smith; Jonathan E. Matthews; Clarence W. Potter; Michael E. Woods; Mathew Raynor; Eric M. Wallen; W. Kimryn Rathmell; Young E. Whang; William Y. Kim; et al.

Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database-UNC GOLD
Urologic Oncology: Seminars and Original Investigations. 2013.

0
4.
2013

Young E. Whang; Andrew J. Armstrong; W. Kimryn Rathmell; Paul A. Godley; William Y. Kim; Raj S. Pruthi; Eric M. Wallen; Jeffrey M. Crane; Dominic T. Moore; Gayle Grigson; et al.

A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer
Urologic Oncology: Seminars and Original Investigations. 2013;31(1):82-86.

0
5.
2012

W. Marston Linehan; W. Kimryn Rathmell

Kidney cancer
Urologic Oncology: Seminars and Original Investigations. 2012;30(6):948-951.

0
6.
2012

Amir H. Khandani; C. Lance Cowey; Dominic T. Moore; Harsh Gohil; Wendy Kimryn Rathmell

Primary renal cell carcinoma: Relationship between ¹⁸F-FDG uptake and response to neoadjuvant sorafenib
Nuclear Medicine Communications. 2012;33(9):967-973.

0
7.
2012

Amir H. Khandani; W. Kimryn Rathmell

Positron emission tomography in renal cell carcinoma: An imaging biomarker in development
Seminars in Nuclear Medicine. 2012;42(4):221-230.

1
8.
2012

Eric Jonasch; P. Andrew Futreal; Ian J. Davis; Sean T. Bailey; William Y. Kim; James Brugarolas; Amato J. Giaccia; Ghada Kurban; Armin Pause; Judith Frydman; et al.

State of the science: An update on renal cell carcinoma
Molecular Cancer Research. 2012;10(7):859-880.

6
9.
2012

Ankur M. Manvar; W. Kimryn Rathmell; Jed Ferguson; Raj S. Pruthi; Matthew E. Nielsen; Eric M. Wallen; Norris Nolan; Mathew C. Raynor

Carcinoma in a cadaveric transplant kidney
Urology. 2012;79(4):758-760.

0
10.
2012

A. Rose Brannon; Scott M. Haake; Kathryn E. Hacker; Raj S. Pruthi; Eric M. Wallen; Matthew E. Nielsen; W. Kimryn Rathmell

Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology
European Urology. 2012;61(2):258-268.

6
11.
2012

Armin M. Gamper; Xinxian Qiao; Jennifer Kim; Liyong Zhang; Michelle C. De Simone; W. Kimryn Rathmell; Yong Wan

Regulation of KLF4 Turnover Reveals an Unexpected Tissue-Specific Role of pVHL in Tumorigenesis
Molecular Cell. 2012;45(2):233-243.

0
12.
2012

Ronald C. Chen; Julian G. Rosenman; Leroy G. Hoffman; Wing-Keung Chiu; Andrew Z. Wang; Raj S. Pruthi; Eric M. Wallen; Jeffrey M. Crane; William Y. Kim; W. Kimryn Rathmell; et al.

Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer
BJU International. 2012.

0
13.
2011

William Y. Kim; Young E. Whang; Raj S. Pruthi; Maria Q. Baggstrom; W. Kimryn Rathmell; Julian G. Rosenman; Eric M. Wallen; Lav K. Goyal; Gayle Grigson; Catharine Watkins; et al.

Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial
Urologic Oncology: Seminars and Original Investigations. 2011;29(6):608-613.

2
14.
2011

Egbert Oosterwijk; W. Kimryn Rathmell; Kerstin Junker; A. Rose Brannon; Frédéric Pouliot; David S. Finley; Peter F.A. Mulders; Ziya Kirkali; Hirotsugo Uemura; Arie Belldegrun

Basic research in kidney cancer
European Urology. 2011;60(4):622-633.

13
15.
2011

Brian L. Teng; Kathryn E. Hacker; Shufen Chen; Anthony R. Means; W. Kimryn Rathmell

Tumor suppressive activity of prolyl isomerase Pin1 in renal cell carcinoma
Molecular Oncology. 2011;5(5):465-474.

0
16.
2011

Neal Rasmussen; W. Kimryn Rathmell

Looking beyond inhibition of VEGF/mTOR: Emerging targets for renal cell carcinoma drug development
Current Clinical Pharmacology. 2011;6(3):199-206.

2
17.
2011

Raj Kurpad; William Kim; W. Kim Rathmell; Paul Godley; Young Whang; Julia Fielding; LuAnn Smith; Ava Pettiford; Heather Schultz; Matthew Nielsen; et al.

A multidisciplinary approach to the management of urologic malignancies: Does it influence diagnostic and treatment decisions?
Urologic Oncology: Seminars and Original Investigations. 2011;29(4):378-382.

2
18.
2010

Kathryn E. Hacker; W. Kimryn Rathmell

Emerging molecular classification in renal cell carcinoma: Implications for drug development
Targeted Oncology. 2010;5(2):75-84.

1
19.
2010

W. Kimryn Rathmell; Paul A. Godley

Recent updates in renal cell carcinoma
Current Opinion in Oncology. 2010;22(3):250-256.

10
20.
2010

C. Lance Cowey; Julia R. Fielding; W. Kimryn Rathmell

The Loss of Radiographic Enhancement in Primary Renal Cell Carcinoma Tumors Following Multitargeted Receptor Tyrosine Kinase Therapy is an Additional Indicator of Response
Urology. 2010;75(5):1108-1113.e1.

11
21.
2010

W. Kimryn Rathmell; C. Lance Cowey; Julia R. Fielding

Reply
Urology. 2010;75(5):1115.

0
22.
2010

Huiqing Liu; Angela R. Brannon; Anupama R. Reddy; Gabriela Alexe; Michael W. Seiler; Alexandra Arreola; Jay H. Oza; Ming Yao; David Juan; Louis S. Liou; et al.

Identifying mRNA targets of microRNA dysregulated in cancer: With application to clear cell Renal Cell Carcinoma
BMC Systems Biology. 2010;4.

49
23.
2010

Tricia M. Wright; W. Kimryn Rathmell

Identification of Ror2 as a hypoxia-inducible factor target in von Hippel-Lindau-associated renal cell carcinoma
Journal of Biological Chemistry. 2010;285(17):12916-12924.

4
24.
2010

C. Lance Cowey; Chirag Amin; Raj S. Pruthi; Eric M. Wallen; Matthew E. Nielsen; Gayle Grigson; Cathy Watkins; Keith V. Nance; Jeffrey Crane; Mark Jalkut; et al.

Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma
Journal of Clinical Oncology. 2010;28(9):1502-1507.

65
25.
2010

Shufen Chen; Christie A. Sanford; Junjiang Sun; Vivian Choi; Terry Van Dyke; R. Jude Samulski; W. Kimryn Rathmell

VHL and PTEN loss coordinate to promote mouse liver vascular lesions
Angiogenesis. 2010;13(1):59-69.

3
26.
2010

W. Kimryn Rathmell; Raj Pruthi; Eric Wallen

Neoadjuvant treatment of renal cell carcinoma
Urologic Oncology: Seminars and Original Investigations. 2010;28(1):69-73.

8
27.
2010

A. Rose Brannon; Anupama Reddy; Michael Seiler; Alexandra Arreola; Dominic T. Moore; Raj S. Pruthi; Eric M. Wallen; Matthew E. Nielsen; Huiqing Liu; Katherine L. Nathanson; et al.

Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns
Genes and Cancer. 2010;1(2):152-163.

31
28.
2010

A. Rose Brannon; W. Kimryn Rathmell

Renal cell carcinoma: Where will the state-of-the-art lead us?
Current Oncology Reports. 2010;12(3):193-201.

9
29.
2009

Alexander A. Benders; Weihua Tang; Jaap M. Middeldorp; Astrid E. Greijer; Leigh B. Thorne; William K. Funkhouser; W. Kimryn Rathmell; Margaret L. Gulley

Epstein-Barr virus latent membrane protein 1 is not associated with vessel density nor with hypoxia inducible factor 1 alpha expression in nasopharyngeal carcinoma tissue
Head and Neck Pathology. 2009;3(4):276-282.

2
30.
2009

T.M. Wright; A.R. Brannon; J.D. Gordan; A.J. Mikels; C. Mitchell; S. Chen; I. Espinosa; M. Van De Rijn; R. Pruthi; E. Wallen; et al.

Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma
Oncogene. 2009;28(27):2513-2523.

17
31.
2009

C.M. Lee; M.M. Hickey; C.A. Sanford; C.G. McGuire; C.L. Cowey; M.C. Simon; W.K. Rathmell

VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo
Oncogene. 2009;28(14):1694-1705.

11
32.
2009

C. Lance Cowey; W. Kimryn Rathmell

VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy
Current Oncology Reports. 2009;11(2):94-101.

16
33.
2008

John D. Gordan; Priti Lal; Vijay R. Dondeti; Richard Letrero; Krishna N. Parekh; C. Elisa Oquendo; Roger A. Greenberg; Keith T. Flaherty; W. Kimryn Rathmell; Brian Keith; et al.

HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma
Cancer Cell. 2008;14(6):435-446.

150
34.
2008

Kathryn E. Hacker; Caroline Martz Lee; W. Kimryn Rathmell

VHL type 2B mutations retain VBC complex form and function
PLoS ONE. 2008;3(11).

7
35.
2008

Chirag Amin; Eric Wallen; Raj S. Pruthi; Benjamin F. Calvo; Paul A. Godley; W. Kimryn Rathmell

Preoperative Tyrosine Kinase Inhibition as an Adjunct to Debulking Nephrectomy
Urology. 2008;72(4):864-868.

50
36.
2008

W. Kimryn Rathmell; J. Paul Monk

High-Dose-Intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review
Urology. 2008;72(3):659-663.

9
37.
2008

Brian I. Rini; W. Kimryn Rathmell; Paul Godley

Renal cell carcinoma
Current Opinion in Oncology. 2008;20(3):300-306.

22
38.
2008

C. Lance Cowey; W. Kimryn Rathmell

Using molecular biology to develop drugs for renal cell carcinoma
Expert Opinion on Drug Discovery. 2008;3(3):311-327.

5
39.
2008

W. Kimryn Rathmell; Shufen Chen

VHL inactivation in renal cell carcinoma: Implications for diagnosis, prognosis and treatment
Expert Review of Anticancer Therapy. 2008;8(1):63-73.

23
40.
2007

Michele M. Hickey; Jennifer C. Lam; Natalie A. Bezman; W. Kimryn Rathmell; M. Celeste Simon

Von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2α signaling and splenic erythropoiesis
Journal of Clinical Investigation. 2007;117(12):3879-3889.

45
41.
2007

Jared A. Gollob; W.Kimryn Rathmell; Tina M. Richmond; Christine B. Marino; Elizabeth K. Miller; Gayle Grigson; Catharine Watkins; Lin Gu; Bercedis L. Peterson; John J. Wright

Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer
Journal of Clinical Oncology. 2007;25(22):3288-3295.

121
42.
2007

W. Kimryn Rathmell; Caroline A. Martz; Brian I. Rini

Renal cell carcinoma
Current Opinion in Oncology. 2007;19(3):234-240.

7
43.
2007

Brian I. Rini; W. Kimryn Rathmell

Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma
Clinical Cancer Research. 2007;13(2 II):741s-744s.

26
44.
2006

Brian I. Rini; Steven C. Campbell; W. Kimryn Rathmell

Renal cell carcinoma
Current Opinion in Oncology. 2006;18(3):289-296.

12
45.
2005

W.K. Rathmell; M.C. Simon

VHL: Oxygen sensing and vasculogenesis
Journal of Thrombosis and Haemostasis. 2005;3(12):2627-2632.

3
46.
2005

W. Kimryn Rathmell; Tricia M. Wright; Brian I. Rini

Molecularly targeted therapy in renal cell carcinoma
Expert Review of Anticancer Therapy. 2005;5(6):1031-1040.

29
47.
2005

W. Kimryn Rathmell; Paul A. Godley; Brian I. Rini

Renal cell carcinoma
Current Opinion in Oncology. 2005;17(3):261-267.

7
48.
2004

W. Kimryn Rathmell; Michele M. Hickey; Natalie A. Bezman; Christie A. Chmielecki; Natalie C. Carraway; M. Celeste Simon

In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations
Cancer Research. 2004;64(23):8595-8603.

35
49.
2004

W. Kimryn Rathmell; Paul A. Godley

Renal cell carcinoma
Current Opinion in Oncology. 2004;16(3):247-252.

5
50.
2004

W. Kimryn Rathmell; S. Bruce Malkowicz; Christopher Holroyde; Will Luginbuhl; David J. Vaughn

Phase II Trial of 5-Fluorouracil and Leucovorin in Combination with Interferon-alpha and Interleukin-2 for Advanced Renal Cell Cancer
American Journal of Clinical Oncology: Cancer Clinical Trials. 2004;27(2):109-112.

5
51.
2004

W. Kimryn Rathmell; Geza Acs; M. Celeste Simon; David J. Vaughn

HIF Transcription Factor Expression and Induction of Hypoxic Response Genes in A Retroperitoneal Angiosarcoma
Anticancer Research. 2004;24(1):167-169.

14
52.
2003

Fiona A. Mack; W. Kimryn Rathmell; Andrew M. Arsham; James Gnarra; Brian Keith; M. Celeste Simon

Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth
Cancer Cell. 2003;3(1):75-88.

98
53.
1999

W. Kimryn Rathmell; Paul Arguin; Stephanie Chan; Albert Yu

Patient with non-insulin-dependent diabetes mellitus
Western Journal of Medicine. 1999;170(2):110-112.

5
54.
1998

Vaughn Smider; W. Kimryn Rathmell; Greg Brown; Susanna Lewis; Gilbert Chu

Failure of hairpin-ended and nickel DNA to activate DNA-dependent protein kinase: Implications for V(D)J recombination
Molecular and Cellular Biology. 1998;18(11):6853-6858.

26
55.
1997

W. Kiniryn Rathmell; William K. Kaufmann; John C. Hurt; Laura L. Byrd; Gilbert Chu

DNA-dependent protein kinase is not required for accumulation of p53 or cell cycle arrest after DNA damage
Cancer Research. 1997;57(1):68-74.

77
56.
1996

Abdellatif Errami; Vaughn Smider; W. Kimryn Rathmell; Dong Ming He; Eric A. Hendrickson; Małgorzata Z. Zdzienicka; Gilbert Chu

Ku86 defines the genetic defect and restores X-ray resistance and V(D)J recombination to complementation group 5 hamster cell mutants
Molecular and Cellular Biology. 1996;16(4):1519-1526.

132
57.
1994

Vaughn Smider; W. Kimryn Rathmell; Michael R. Lieber; Gilbert Chu

Restoration of X-ray resistance and V(D)J recombination in mutant cells by Ku cDNA
Science. 1994;266(5183):288-291.

266
58.
1994

W. Kimryn Rathmell; Gilbert Chu

Involvement of the Ku autoantigen in the cellular response to DNA double-strand breaks
Proceedings of the National Academy of Sciences of the United States of America. 1994;91(16):7623-7627.

141
59.
1994

W. Kimryn Rathmell; Gilbert Chu

A DNA end-binding factor involved in double-strand break repair and V(D)J recombination
Molecular and Cellular Biology. 1994;14(7):4741-4748.

114
60.
1992

D.J. Wiens; T.K. Mann; D.E. Fedderson; W.K. Rathmell; B.H. Franck

Early heart development in the chick embryo: Effects of isotretinoin on cell proliferation, α-actin synthesis, and development of contractions
Differentiation. 1992;51(2):105-112.

17

Wendy Kimryn Rathmell UNCCH, School of Medicine, Medicine

Wendy Kimryn Rathmell

Wendy Kimryn Rathmell
UNCCH, School of Medicine, Medicine